Ultragenyx Pharma (RARE) Misses Q1 EPS by 79c, Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Ultragenyx Reports First Quarter 2021 Financial Results and Corporate Update
May 4, 2021 4:01 PM EDTFirst quarter 2021 total revenue of $99.4 million and Crysvita1 revenue to Ultragenyx of $42.1 million
2021 Crysvita revenue in Ultragenyx territories1 guidance of $180 million to $190 million reaffirmed
Strong Dojolvi launch continues with approximately 180 patients on reimbursed commercial therapy in the United States
NOVATO, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultra-rare genetic diseases, today reported its financial results for the... More
